###begin article-title 0
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Vitamin D receptor gene BsmI polymorphisms in Thai patients with systemic lupus erythematosus
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 586 591 586 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 1023 1025 1023 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1102 1104 1102 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1317 1322 1317 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
###xml 693 701 <span type="species:ncbi:9606">patients</span>
The immunomodulatory role of 1,25-dihydroxyvitamin D3 is well known. An association between vitamin D receptor (VDR) gene BsmI polymorphisms and systemic lupus erythematosus (SLE) has been reported. To examine the characteristics of VDR gene BsmI polymorphisms in patients with SLE and the relationship of polymorphisms to the susceptibility and clinical manifestations of SLE, VDR genotypings of 101 Thai patients with SLE and 194 healthy controls were performed based on polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The relationship between VDR gene BsmI polymorphisms and clinical manifestations of SLE was evaluated. The distribution of VDR genotyping in patients with SLE was 1.9% for BB (non-excisable allele homozygote), 21.78% for Bb (heterozygote), and 76.23% for bb (excisable allele homozygote). The distribution of VDR genotyping in the control group was 1.03% for BB, 15.98% for Bb, and 82.99% for bb. There was no statistically significant difference between the two groups (p = 0.357). The allelic distribution of B and b was similar within the groups (p = 0.173). The relationship between VDR genotype and clinical manifestation or laboratory profiles of SLE also cannot be statistically demonstrated. In conclusion, we cannot verify any association between VDR gene BsmI polymorphism and SLE. A larger study examining other VDR gene polymorphisms is proposed.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 362 363 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 838 845 830 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1004 1005 996 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1125 1126 1117 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1250 1251 1242 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1279 1280 1271 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 990 996 <span type="species:ncbi:10090">murine</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
The importance of genetic influences on systemic lupus erythematosus (SLE) has been recognized through cumulative genetic epidemiologic studies. Many population-based studies have shown associations between the disease and alleles of immunologically relevant genes, including certain major histocompatibility complex (MHC) loci, Fcgamma receptor, and cytokines [1]. 1,25-dihydroxyvitamin D3 is thought to exert many of its action through interaction with a specific intracellular receptor. At the molecular level, 1,25-dihydroxyvitamin D3 inhibits the accumulation of mRNA for interleukin (IL)-2, interferon (IFN)-gamma, and granulocyte-macrophage colony-stimulating factor (GM-CSF). At the cellular level, the hormone interferes with T helper cell (Th) function, reducing Th induction of immunoglobulin production by B cells. When given in vivo, 1,25-dihydroxyvitamin D3 has been particularly effective in prevention of autoimmune diseases such as experimental autoimmune encephalitis and murine lupus [2]. It has been demonstrated that patients with SLE have a lower level of 25 hydroxyvitamin D3 than do healthy controls [3]. In addition, high-dose 1,25-dihydroxyvitamin D3 and its analog may be useful therapeutic agents for psoriatic arthritis [4] and rheumatoid arthritis [5].
###end p 4
###begin p 5
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 576 581 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
Polymorphism of the vitamin D receptor (VDR) gene was found to be associated with many diseases, including osteoporosis [6], hyperparathyroidism [7], and prostate cancer [8]. An association between VDR gene polymorphism and SLE in Japanese and Chinese patients has been reported with mixed results [9-11]. Although Asians are closely related ethnically, the genetic admixture in Japan or China is different from that of Thailand. Because a high prevalence and high clinical severity of SLE are also observed in the Thai population, we examined the characteristics of VDR gene BsmI polymorphisms in a larger cohort of Thai patients with SLE and the relationship of polymorphisms to the susceptibility and clinical manifestations of SLE.
###end p 5
###begin title 6
Materials and methods
###end title 6
###begin p 7
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 223 231 <span type="species:ncbi:9606">patients</span>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
This study was conducted in accordance with the principles embodied in the Declaration of Helsinki and was approved by the ethical committees of the Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. DNA from 101 patients with SLE was examined. All patients fulfilled the 1982 revised criteria for SLE [12]. All were females older than 15 years of age. They did not meet criteria for other autoimmune diseases. DNA from 194 unrelated healthy subjects served as controls. All healthy subjects were females older than 15 years of age. VDR genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
###end p 7
###begin p 8
###xml 380 385 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 584 586 580 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Genomic DNA was extracted from peripheral white blood cells using standard phenol-chloroform method. PCR was carried out in a final reaction volume of 50 mul. Oligonucleotide primers designed to anneal to exon 7 (primer 1, 5' CAACCAAGACTACAAGTACCGCGTCAGTGA-3') and intron 8 (primer 2, 5'-AACCAGCGGGAAGAGGTCAAGGG-3') were used to amplify 825 bp fragment, including the polymorphic BsmI site in intron 7 of the gene. The following reagents were added to a 200-mul ultramicrocentrifuge tube: 5 mul of 10 x buffer (100 mM Tris HCl pH 9.0, 500 mM KCl, and 1.0% Triton x-100), 2 mul of MgCl2 (25 mM), 3 mul of deoxynucleotide triphosphate (2 mM each) (Promega, Madison, WI, USA), 0.5 mul of primer 1 (20 muM), 0.5 mul of primer 2 (20 muM), 2.5 units of Taq DNA polymerase (Promega), 300 ng of template DNA, and water to a final volume of 50 mul.
###end p 8
###begin p 9
The cycling condition was set as follows: one cycle at 95degreesC for 3 minutes, 30 cycles at 95degreesC for 30 seconds, 56degreesC for 30 seconds, and 72degreesC for 30 seconds. One final cycle of the extension was performed at 72degreesC for 10 minutes.
###end p 9
###begin p 10
One microliter of the PCR product was digested at 65degreesC for 1 hour in the final volume of 10 mul with 5 units of restriction enzyme BsmI (New England Biolabs Inc., Ipswich, MA, USA) in 1 x buffer. The digested samples were fractionated by electrophoresis in a 1.5% agarose gel. Restriction fragments were detected by staining with ethidium bromide, and genotypes were determined by comparing the restriction length polymorphism band patterns with a 100 bp DNA ladder run on the same gel. The presence of the BsmI restriction site generated 175 bp and 650 bp fragments, whereas the absence of this site yielded an 825 bp fragment.
###end p 10
###begin p 11
The genotypes were classified as excisable allele homozygote (bb), non-excisable allele homozygote (BB), and heterozygote (Bb).
###end p 11
###begin title 12
Statistical analysis
###end title 12
###begin p 13
###xml 132 134 121 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 233 235 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Analyses were performed with Epi Infotrade mark 2002 Results from patients with SLE and control subjects were compared using the chi2 test for statistical significance. Hardy-Weinberg equilibrium (HWE) was determined by Pearson's chi2 goodness-of-fit test.
###end p 13
###begin title 14
Results
###end title 14
###begin p 15
###xml 290 292 290 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 391 393 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 401 403 399 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 417 419 413 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 427 429 423 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 523 525 519 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 541 542 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 684 685 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
The distribution of VDR genotyping in patients with SLE was 1.9% for BB, 21.78% for Bb, and 76.23% for bb. The distribution of VDR genotyping in the control group was 1.03% for BB, 15.98% for Bb, and 82.99% for bb. There was no statistically significance difference between the two groups (p = 0.357) (Table 1). The genotype frequencies were consistent with HWE in patients and controls (chi2 = 0.08, p = 0.77 and chi2 = 0.14, p = 0.71, respectively). The allelic distribution of B and b was similar within the two groups (p = 0.173) (Table 2). The relationship between VDR genotype and clinical manifestation or laboratory profiles of SLE cannot be statistically demonstrated (Table 3).
###end p 15
###begin title 16
Dicussion
###end title 16
###begin p 17
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 639 641 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 642 644 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 691 693 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 929 931 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1086 1088 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Most tissues in the body, including heart, stomach, pancreas, bone, skin, gonads, and activated T and B lymphocytes, have the nuclear receptor for 1,25-dihydroxyvitamin D3 (VDR). Thus, it is not surprising that 1,25-dihydroxyvitamin D3 has a multitude of biologic effects that are non-calcemic in nature [13]. Recent research shows that the biologic action of vitamin D extends well beyond the classic function to include effects on immunity, muscle and vasculature, reproduction, and the growth and differentiation of many cell types [14]. 1,25-Dihydroxyvitamin D3 directly inhibits synthesis and secretion of IL-2 [15,16] and IFN-gamma [17,18] and also inhibits immunoglobulin production [19]. Genomic actions of 1,25-dihydroxyvitamin D3 are mediated through its nuclear receptor (VDR). The VDR regulates gene transcription by binding to the hexameric core binding motif in promoter region of target genes, VDR element (VDRE) [17]. Extensive studies focused on this VDR gene in various phenotypes have revealed the association between VDR polymorphism and many non-skeletal diseases [20].
###end p 17
###begin p 18
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 268 270 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 480 482 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 474 478 <span type="species:ncbi:10090">mice</span>
Although SLE has features consistent with Th2-type cytokine predominance, both Th1 and Th2 cytokine may be involved in the pathogenesis of SLE [21]. Mononuclear cells of patients with SLE have defects in IL-2 signal transduction and decreased production of IFN-gamma [22]. IFN-gamma, tumor necrosis factor (TNF)-alpha, and IL-1 are the most important adhesion molecules inducing cytokine, and they increase in autoimmune renal disease, particularly in Mrl/lpr-Fas and NZB/W mice [23].
###end p 18
###begin p 19
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 924 929 924 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
Recently, VDR gene BsmI polymorphisms have been used as genetic markers to determine their association with SLE [9-11]. A Japanese study of 58 patients with SLE found that the BB genotype might trigger the development of SLE and that the bb genotype was associated with lupus nephritis [9]. A Taiwanese study[10] of 47 Chinese patients with SLE also found an increased distribution of the VDR BB genotype in SLE but indicated no association between the frequency of VDR allelic variations and clinical manifestations or laboratory profiles. In our study, the BB genotype is low in both 194 healthy controls and 101 patients with SLE. However, this is in accordance with previous findings in the Thai population [24]. Thailand is geographically situated in an area between China and India. This genetic admixture may influence the distribution of VDR gene polymorphism. We cannot demonstrate any association between VDR gene BsmI polymorphism and SLE. We further examined the relationship between VDR genotype and the individual clinical manifestation or laboratory profiles of SLE, which also cannot be statistically demonstrated.
###end p 19
###begin title 20
Conclusion
###end title 20
###begin p 21
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BsmI </italic>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 360 368 <span type="species:ncbi:9606">patients</span>
It was apparent that compared with the genotype distribution of the VDR gene reported in previous studies [9-11], the genotype frequencies in Thais were different. Because our study includes a larger number of patients and controls than any previous study, we conclude that there is no association between VDR gene BsmI polymorphisms and SLE, at least in Thai patients. We propose that other VDR gene polymorphisms be examined.
###end p 21
###begin title 22
Abbreviations
###end title 22
###begin p 23
bb = excisable allele homozygote; Bb = heterozygote; BB = non-excisable allele homozygote; HWE = Hardy-Weinberg equilibrium; IFN = interferon; IL = interleukin; SLE = systemic lupus erythematosus; Th = T helper cell; VDR = vitamin D receptor.
###end p 23
###begin title 24
Competing interests
###end title 24
###begin p 25
The authors declare that they have no competing interests.
###end p 25
###begin title 26
Authors' contributions
###end title 26
###begin p 27
WS conceived of the study, and participated in its design, coordination and acquisition of data. OV carried out the molecular genetic study and performed statistical analysis. KN and KT participated in coordination and interpretation of data. PL participated in acquisition of data and helped in drafting and revising the manuscript. SJ have been involved in drafting and revising the manuscript for important intellectual content and have given final approval of the version to be published. All authors read and approved the final manuscript.
###end p 27
###begin title 28
Acknowledgements
###end title 28
###begin p 29
The work was supported by a grant from the Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
###end p 29
###begin article-title 30
Immunomodulatory role of 1,25-dihydroxyvitamin D3
###end article-title 30
###begin article-title 31
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus
###end article-title 31
###begin article-title 32
Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study
###end article-title 32
###begin article-title 33
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients
###end article-title 33
###begin article-title 34
Genetics of osteoporosis
###end article-title 34
###begin article-title 35
###xml 124 129 <span type="species:ncbi:9606">human</span>
Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors
###end article-title 35
###begin article-title 36
Association of prostate cancer with vitamin D receptor haplotypes in African-Americans
###end article-title 36
###begin article-title 37
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus
###end article-title 37
###begin article-title 38
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Association of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus
###end article-title 38
###begin article-title 39
###xml 85 93 <span type="species:ncbi:9606">patients</span>
No association of vitamin D receptor gene start codon fok 1 polymorphisms in Chinese patients with systemic lupus erythematosus
###end article-title 39
###begin article-title 40
The 1982 revised criteria for the classification of systemic lupus erythematosus
###end article-title 40
###begin article-title 41
Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis
###end article-title 41
###begin article-title 42
Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure
###end article-title 42
###begin article-title 43
###xml 79 87 79 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 36 41 <span type="species:ncbi:9606">human</span>
1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro
###end article-title 43
###begin article-title 44
###xml 52 57 <span type="species:ncbi:9606">human</span>
Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production
###end article-title 44
###begin article-title 45
Immunosuppressive actions of 1, 25-Dihydroxyvitamin D3: Preferential inhibition of Th1 functions
###end article-title 45
###begin article-title 46
###xml 77 82 <span type="species:ncbi:9606">human</span>
1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes
###end article-title 46
###begin article-title 47
###xml 42 50 42 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
The effect of 1,25-dihydroxyvitamin D3 on in vitro immunoglobulin production in human B cells
###end article-title 47
###begin article-title 48
Genetics of osteoporosis
###end article-title 48
###begin article-title 49
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production
###end article-title 49
###begin article-title 50
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Deficient gamma-interferon production in patients with systemic lupus erythematosus
###end article-title 50
###begin article-title 51
Cytokines in the pathogenesis of systemic lupus erythematosus
###end article-title 51
###begin article-title 52
###xml 134 139 <span type="species:ncbi:9606">women</span>
Vitamin D receptor gene polymorphism is associated with urinary calcium excretion but not with bone mineral density in postmenopausal women
###end article-title 52
###begin title 53
Figures and Tables
###end title 53
###begin p 54
###xml 34 42 <span type="species:ncbi:9606">patients</span>
Distribution of VDR genotyping in patients with SLE and healthy controls
###end p 54
###begin p 55
###xml 3 5 1 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 19 21 17 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 66 68 62 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 76 78 72 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 104 106 98 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 114 116 108 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
chi2 test = 2.062, p = 0.357. Hardy-Weinberg equilibrium test: chi2 = 0.08, p = 0.77 in patients and chi2 = 0.14, p = 0.71 in controls. bb = excisable allele homozygote; Bb = heterozygote; BB = non-excisable allele homozygote; SLE, systemic lupus erythematosus; VDR, vitamin D receptor.
###end p 55
###begin p 56
###xml 25 33 <span type="species:ncbi:9606">patients</span>
VDR allelic frequency in patients with SLE and healthy controls
###end p 56
###begin p 57
###xml 3 5 1 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 19 21 17 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
chi2 test = 2.125, p = 0.145. b, excisable allele; B, non-excisable allele; SLE, systemic lupus erythematosus; VDR, vitamin D receptor.
###end p 57
###begin p 58
Relationship between VDR genotype and clinical manifestation or laboratory profiles of SLE
###end p 58
###begin p 59
ANA = anti-nuclear antibodies; bb = excisable allele homozygote; Bb = heterozygote; BB = non-excisable allele homozygote; SLE, systemic lupus erythematosus; Sm = Smith; VDR, vitamin D receptor.
###end p 59

